Kyowa Kirin Co. Ltd.

4151

JP3256000005

Pharmaceuticals

Market Closed - Japan Exchange Other stock markets 02:00:00 2024-04-26 am EDT			5-day change	1st Jan Change
2,630 ^JPY	+0.23%		+0.80%	+10.97%

Apr. 08	U.S. FDA declines to approve Supernus' drug-device combination for Parkinson's disease	RE
Apr. 03	Kyowa Kirin Buys Back 4 Billion Yen Worth of Shares in March	MT

Kyowa Kirin Co., Ltd. Provides Consolidated Earnings Guidance for the Full Year Ending December 31, 2024

February 07, 2024 at 01:30 am EST

Kyowa Kirin Co., Ltd. provided consolidated earnings guidance for the full year ending December 31, 2024. For the full year, the company expects net revenue of JPY 473,000 million, core operating profit of JPY 85,000 million and profit of JPY 63,000 million or JPY 119.07 per basic share.

Latest news about Kyowa Kirin Co. Ltd.

U.S. FDA declines to approve Supernus' drug-device combination for Parkinson's disease	Apr. 08	RE
Kyowa Kirin Buys Back 4 Billion Yen Worth of Shares in March	Apr. 03	MT
Tranche Update on Kyowa Kirin Co., Ltd.'s Equity Buyback Plan announced on February 7, 2024.	Apr. 02	CI
Japanese Shares Slip into Red Amid Profit-Taking; Tokyo Inflation Eyed	Mar. 25	MT
Kyowa Kirin to Allocate Over 84,000 Treasury Shares as Director, Officer Compensation	Mar. 25	MT
Kyowa Kirin's gene therapy most expensive US drug with $4.3 million price tag	Mar. 20	RE
US approves first gene therapy for children with rare genetic disease	Mar. 18	RE
US approves first gene therapy for rare genetic disease	Mar. 18	RE
Kyowa Kirin Co., Ltd. to Present Phase 2B Post-Hoc Analysis and Symposium At the American Academy of Dermatology Annual Meeting 2024	Mar. 08	CI
Kyowa Kirin Buys Back Nearly 3 Billion Yen of Shares	Mar. 05	MT
China Deflation, Bank of Japan Roil Asian Stock Markets	Feb. 08	MT
Japan's Nikkei closes at 34-year peak on dovish BOJ; tech shares soar	Feb. 08	RE
Japan's Nikkei leaps to 2-week high on tech stocks, yen boost	Feb. 07	RE
BridgeBio Pharma Unit to Grant Kyowa Kirin License for Infigratinib in Japan	Feb. 07	MT
Kyowa Kirin's Profit Up 52% in Fiscal 2023	Feb. 07	MT
Kyowa Kirin Co., Ltd. Provides Dividend Guidance for the Year Ending December 31, 2024	Feb. 07	CI
Kyowa Kirin Co., Ltd. Declares Dividend for the Fiscal Year Ended December 31, 2023, Payable on March 25, 2024; Provides Dividend Guidance for the Second Quarter of 2024	Feb. 07	CI
Kyowa Kirin Co., Ltd. Provides Consolidated Earnings Guidance for the Full Year Ending December 31, 2024	Feb. 07	CI
Kyowa Kirin Co., Ltd. announces an Equity Buyback for 17,000,000 shares, representing 3.16% for KRW 40,000 million.	Feb. 07	CI
Kyowa Hakko Kirin Co., Ltd. authorizes a Buyback Plan.	Feb. 06	CI
Kyowa Kirin Announces First Patient Enrolled in the Phase 2 Clinical Trial Evaluating Tivozanib Eye Drops in Patients with Diabetic Macular Edema	Feb. 06	CI
Japanese Shares Skid as Inflation Slows Faster-than-Expected in January	Jan. 26	MT
Kyowa Kirin Acquires All Outstanding Shares of Orchard Therapeutics	Jan. 25	MT
Orchard Therapeutics Completes Sale to Japan's Kyowa Kirin	Jan. 24	MT
Kyowa Kirin Co., Ltd. completed the acquisition of Orchard Therapeutics plc from RA Capital Management, L.P., Deep Track Capital, LP, Zentree Investment Management Pte. Ltd. and others.	Jan. 23	CI

Chart Kyowa Kirin Co. Ltd.

Duration

Period

More charts

Company Profile

Kyowa Kirin Co., Ltd. specializes in the development, manufacturing and marketing of pharmaceutical and biochemical products. Net sales break down by source of revenue as follows: - sales of pharmaceutical products (92.6%): prescription products for anemia, cancers, immune and nephrology diseases treatment; - sales of licenses (7.4%). At the end of 2021, the group had 3 production sites located in Japan (2) and China. Net sales break down geographically as follows: Japan (60.9%), Asia (9%), Americas (16.3%) and Europe (13.8%).

Sector

Pharmaceuticals

Calendar

2024-05-06 - Q1 2024 Earnings Release

Related indices

Nikkei 225

More about the company

Income Statement Evolution

More financial data

Ratings for Kyowa Kirin Co. Ltd.

Trading Rating

Investor Rating

ESG Refinitiv

A-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

2,630 JPY

Average target price

3,067 JPY

Spread / Average Target

+16.60%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Specialty & Advanced Pharmaceuticals

	1st Jan change	Capi.
KYOWA KIRIN CO. LTD.	+10.97%	8.94B
MERCK KGAA	+5.31%	70.44B
SK BIOPHARMACEUTICALS CO., LTD.	-16.83%	4.75B
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD.	+43.48%	4.5B
YUHAN CORPORATION	+3.20%	3.85B
INDIVIOR PLC	+18.82%	2.38B
BETTA PHARMACEUTICALS CO., LTD.	-21.36%	2.34B
CHANGCHUN BCHT BIOTECHNOLOGY CO.	-29.67%	2.2B
SHANGHAI SHYNDEC PHARMACEUTICAL CO., LTD.	+8.38%	1.96B
SUPERNUS PHARMACEUTICALS, INC.	+3.90%	1.65B

Specialty & Advanced Pharmaceuticals